ZymoGenetics keeps Merrill's buy rating

ZymoGenetics, Inc. was maintained at a buy by Merrill Lynch analyst Hari Sambasivam. The company reported first-quarter financial results in line with Merrill's estimates. Total revenues were $7.4 million, compared with the analyst's estimate of $9.3 million. The reported net loss of $31.7 million, or $0.48 per share, compared favorably with Merrill's estimate of $30 million, or $0.46 per share. The analyst revised his 2006 loss-per-share estimate to $2.11 from $2.20. Shares of the Seattle biotechnology company were up 96 cents, or 4.77%, at $21.07 on volume of 372,597 shares versus the three-month running average of 323,550 shares. (Nasdaq: ZGEN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.